Member Info for Moneymunch

Frigging in the rigging. ...Gl :-)))

  

Shallow water drilling contractor Borr Drilling said Tuesday it had recently secured awards for two offshore rigs in West Africa.

"In late August 2021, the company entered into two LOA/LOIs which have previously not been announced for two rigs in West Africa for a total duration of two years plus options,” Borr Drilling said Tuesday as part of its quarterly report.

Borr Drilling’s accompanying fleet status report revealed that the two jack-up rigs in question are the Frigg and the Natt.

The company has signed a letter of intent for the Frigg for deployment either in December 2021 or January 2022, till December 2022 in West Africa, with an undisclosed client. The Frigg, built in 2013, is currently warm stacked in Cameroon.

For the Natt drilling unit, Borr Drilling has received a letter of award, with the contract expected to start in November 2021, and last until October 2022. As with Frigg, the Natt client’s identity was not shared. 

This contract, too, is for deployment in West Africa. The rig has a contract with Oriental in Nigeria until October 2021.

0  0 0

Maybe one of the following in consideraion??? Gla ;-)

A ready stacked rig typically retains most of its crew and can deploy quickly if an operator requires its services.

Jack-up rigs are mobile, self-elevating drilling and workover platforms equipped with legs that can be lowered to the ocean floor until a foundation is established to support the hull, which contains the drilling and/or workover equipment, jacking system, crew quarters, loading and unloading facilities, storage areas.

Search Criteria

Country : Cameroon

Dagda

Type: Jackup
Manager: Petrofor
Status: Ready Stacked
Owner: Petrofor
Classification: Unknown
Design: LeTourneau
Frigg

Type: Jackup
Manager: Borr Drilling
Status: Ready Stacked
Owner: Borr Drilling
Classification: ABS
Design: Keppel FELS
Gerd

Type: Jackup
Manager: Borr Drilling
Status: Ready Stacked
Owner: Borr Drilling
Classification: ABS
Design: Baker Marine
Groa

Type: Jackup
Manager: Borr Drilling
Status: Ready Stacked
Owner: Borr Drilling
Classification: ABS
Design: Baker Marine
Natt

Type: Jackup
Manager: Borr Drilling
Status: Ready Stacked
Owner: Borr Drilling
Classification:
Design: Baker Marine

0

Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.

.....

5. Conclusions

In this work, we used in vitro and in vivo experimental models to assess the therapeutic potential of SFX-01 for GBM treatment. Our data suggest that SFN targets ER stress and NRF2, paying as a “master regulator” of the body’s stress response. Secondary but very important effects are the inhibition of HDAC activity especially on class I HDACs and inhibition of STAT3 with reduced activity of NFKB pathways which modulate progression of GBM and induce ROS. So, metabolic, oxidative, and epigenetic modifications are the bases of the different effects of SFN. Our study provided detailed evidence that SFX-01 induced cell death and inhibited the growth of GBM cells and xenografts through the modulation of multiple cell-signaling pathways, demonstrating its potential as a new compound for GBM treatment. SFX-01 was also highly effective in eliminating GSCs through the induction of cell differentiation, compared to the less-malignant astrocyte phenotype. SFX-01 also reduced the vasculogenic properties of GBM cells, thus inhibiting the growth of GBM xenografts in vivo. SFX-01 triggered DNA damage and increased RT-mediated ?-H2Ax expression through the production of ROS. Overall, our preclinical data indicated that the effects of SFX-01 are due to multiple molecular mechanisms, participating in switching off autophagy and switching on apoptosis, which are responsible for SFX-01-mediated cell death.

https://www.mdpi.com/1424-8247/14/11/1082/htm

LONDON — Oil prices climbed to multi-year highs shortly after a group of some of the world's most powerful oil producers opted against a big supply boost.

Now energy analysts believe crude prices could be poised to rally toward $100 a barrel.

Interesting and suggestive tweet from Block Energy...Gla holders...Bring on the flow test results...Confirmation of commercial volumes could be Transformational with oil and gas prices heading skywards!!! :-)

Block Energy Plc

@BlockEnergyplc

·

8h

Commodity Giant Trafigura Paints Bullish Outlook for Oil and Gas #BLOE

https://mobile.twitter.com/BlockEnergyplc?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

https://www.bloomberg.com/news/articles/2021-09-27/commodity-giant-trafigura-paints-bullish-outlook-for-oil-and-gas

Brent now at $79 plus and Gas at $5.4 and both rising....not a bad time to announce a commercial discovery and confirm current production figures. Gla ;-)

http://www.livecharts.co.uk/MarketCharts/brent.php

http://www.livecharts.co.uk/MarketCharts/ngas.php

Brent now at $74.14 and rising....and Gas on the surge to new highs. Gla ;-)

http://www.livecharts.co.uk/MarketCharts/brent.php

http://www.livecharts.co.uk/MarketCharts/ngas.php

No placing required if WR-B1 is confirmed commercial ;

9/9/21

" If the well proves to be commercially viable, which we hope to establish soon, Block could readily realise the return on its investment in well WR-B1a, having established Early Production Facilities, which will enable rapid monetisation of both oil & gas. The Company continues with its activity on many fronts, including preparations now underway for the drilling of the second well in the campaign".

and they still have a few quid in the bank and a signifcant increase in value of current assets, which could rise exponentially along with the sp, if the well is commercial ..... Gla ;-)

2/6/21

The Group's financial position has changed significantly over the past year, with Group net assets increasing from $20,610,000 as at 31 December 2019 to $29,866,000 owing to the acquisition of Block Rustaveli Limited and the $7.2 million cash raised in the equity placing in December 2020. At the end of the year, the Group's cash balance was $6,331,000 (2019: $6,494,000).

" encountering hydrocarbon shows higher in the Middle Eocene reservoir than expected. Shows continued to increase in frequency and magnitude".....Gla HOLDERS.....On and UP!!! ;-)

I realise that Nolupus, but the speed of granting Orphan status does seem extraordinary, and so i'm hoping for a partner with influence, and we know how excited Huw was with the initial pre-clinical data from University L'Aquila , which has now also been reproduced by University of Auckland, and so obviously compelling for a speedy decision from the FDA which also might be enough to garner interest or galvanise current interest from a potential suitor. Gl ;-)

13/7/21

Dr Huw Jones, CEO of Evgen, commented: "Given the progress with our glioma programme and our intent to commence trials in 2022, we are seeking Orphan Drug status to maximise our intellectual property protection, commercial potential and partner appeal in this devastating disease. The incentives offered by OD designation mean that rare diseases like glioblastoma are more likely to be researched in the clinic. "

Can't help thinking there could be a significant reason for the speed the FDA granted Orphan Drug designation, especially during the holiday season when you'd expect things to go slow......here's hoping a commercial partner in the pipeline is the reason. Gla ;-)

We knew about the Orphan Drug Designation several hours before the RNS and so no doubt some jumped in and out again with their profits, the sp was also at sub 5p a month or so ago and so plenty banking profits at 8p plus who've bought in on the lows and probably a few pi's who had been sitting in the red since the 8p placing and Covid news......all part of the trading process when shares move UP.....and we're now ready for the next move UP imho, the share float is becoming tight with Mr Kight and co buying and there's plenty of material news from the rest of the pipeline that could drop at anytime and drive the sp back to double figures. Gla holders. :-)

A late reported after hours trade from yesterday, 961k at 8.04p. .....Gla....On and UP!!! ;-)

The speed that Orphan Drug designation has been granted, might suggest that Evgen has a US player with influence, as the application was only made 13th July and so the FDA response appears incredibly rapid compared to normal circumstances . Gla ;-)

Evgen Pharma’s SFX-01 granted orphan drug designation by FDA for malignant glioma treatment

The drug company said the OD designation is part of a wider strategy to access the US market
Evgen Pharma PLC - Evgen Pharma’s SFX-01 granted orphan drug designation by FDA for malignant glioma treatment

Evgen Pharma PLC (AIM:EVG, FRA:8EV) said its SFX-01 drug has been granted an orphan drug designation (OD) by the US Food and Drug Administration (FDA) for the treatment of malignant glioma.

The clinical stage drug development company submitted its application for OD designation on 13 July 2021.

Dr Huw Jones, CEO of Evgen, said: "We are delighted that our team and advisors have successfully gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering.''

An example of a negatively biased blinkered view 27th August...Ho ho ho ho ho.... ;-)

Kingalf

Posted in: EVG

Posts: 266

Price: 6.40

No Opinion

RE: Trading strategy 27 Aug 2021 17:34

Ontarget - Surely your statement on confidence in your convinctions applies to the majority on here as soon as they've topped up, in a desperate sort of way they're trying to convince themselves and others that they haven't thrown good money after bad.
I am right again, we will see the low 5s in the next week or so, Kight is the only buyer keeping this up.

Lol kingalf, back to 8p plus yesterday must have upset you specially when you were bashing at 5p ....ha ha ha ha ....short term profit takers and traders dragged the sp back yesterday, but with Mr Kight and like minded people mopping UP, ( all with a greater appreciation of Evgen's prospects and potential then your negatively biased and blinkered view ) , suggests that the free float of shares is getting tighter and tighter and so continued UPward momentum is very likely, c£12m cash in the bank and a multiple disease pipeline where more news could drop at anytime....Gla Holders.....SFX-01's Orphan Drug Designation granted by the FDA greatly opens up the access to the US markets, investors and potential commercial partners.......it's BIG news for little old Evgen!!! ;-)

0  1 0

Not many shares in free float...Mr Kight has bought them all. Gla :-)

This is big news and the market is unaware. Fill ya Boots!!! :-)

Courtesy of peanut on Advfn....On and UP!!! ;-)

FDA grants orphan drug designation to sulforaphane for malignant glioma (6.4000p, 0)
Wednesday, September 01, 2021 10:05:51 PM (GMT)

According to the FDA's Orphan Drug product website, Evgen Pharma plc has been granted Orphan drug designation for Stabilized sulforaphane for the treatment of malignant glioma.
Designation date 9/1/2021
StreetAccount notes that the name of the drug was not disclosed, but that it is likely SFX-01. Evgen's website notes an ongoing collaboration with a prominent European university in which highly positive data for SFX-01 was generated in preclinical models of glioma.
FDA orphan drug designation is primarily a function of the disease not the drug - drugs that target diseases with fewer than 200,000 US patients will be granted orphan designation, and in some cases drugs targeting more than 200,000 patients can be granted the designation when the FDA judges that costs could not otherwise be recovered.